Literature DB >> 26840652

Modified penetrating keratoplasty with Acell® bioscaffold implant in seven horses with deep full-thickness corneal stromal abscess.

Brian M Cichocki1, Kathern E Myrna1, Phillip A Moore1.   

Abstract

OBJECTIVE: To describe and evaluate a modified penetrating keratoplasty technique utilizing ACell® for management of equine deep stromal or full-thickness corneal stromal abscesses (SA).
METHODS: Cases presenting to the University of Georgia Ophthalmology service for surgical management of SA necessitating penetrating keratoplasty (PK) were included in the study population. Surgery entailed the use of an ACell® disk sutured within the deep level of a stepped full-thickness corneal incision with an overlying conjunctival pedicle flap placed in the superficial step incision. Patients were evaluated for success as defined by a comfortable, visual outcome.
RESULTS: Surgery was performed in seven horses. Conjunctival flap incorporation and globe retention occurred in all patients. Functional vision was maintained in six of seven eyes (85.7%) at last follow-up examination (mean of 87.6 days [range 41-251 days]). Mean size of ACell® implant was six millimeters (range 4-8 mm). Postoperative complications included moderate to severe anterior uveitis (n = 2), diffuse keratitis (n = 1), incipient cataract formation (n = 3), and anterior and posterior synechiae (n = 1).
CONCLUSIONS: This technique is a viable option for treatment of equine SA requiring PK. The use of bioscaffold implant is an alternative to frozen and fresh donor cornea transplantation.
© 2016 American College of Veterinary Ophthalmologists.

Entities:  

Keywords:  acell; acellular submucosa; corneal implant; equine; extracellular matrix; stromal abscess

Mesh:

Year:  2016        PMID: 26840652     DOI: 10.1111/vop.12349

Source DB:  PubMed          Journal:  Vet Ophthalmol        ISSN: 1463-5216            Impact factor:   1.644


  1 in total

1.  [Surgical treatment of a perforated cornea in a zebra].

Authors:  A Steinmetz; A Bernhard; C Minkwitz; D Böttcher
Journal:  Ophthalmologe       Date:  2019-10       Impact factor: 1.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.